Blood Cancer News and Research

RSS

Clinical trial underway for novel human milk-based microbiome therapy

In a breakthrough for human milk science, researchers at City of Hope, Los Angeles, have dosed the first patient in a Phase 2a clinical trial evaluating a novel therapy for blood cancer patients undergoing allogeneic hematopoietic stem cell transplantation.

10 Nov 2023

Targeted drug may offer a new treatment option for patients with relapsed blood cancer

A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), may offer a new treatment option for patients with blood cancers, including chronic lymphocytic leukemia (CLL) and Non-Hodgkin lymphoma (NHL) whose disease has stopped responding to standard treatments.

6 Nov 2023

New study provides insights about mosaic chromosomal alterations in diverse populations

As people age, the DNA in their cells begins to accumulate genetic mutations. Mosaic chromosomal alterations (mCAs), a category of mutations acquired in blood cells, are linked with a 10-fold increased risk of developing blood cancer.

1 Nov 2023

Scientists identify mechanism causing deadly blood clots after some COVID-19 vaccines

A mechanism that led some patients to experience cases of deadly clotting following some types of Covid-19 vaccination has been identified in new research.

30 Oct 2023

MHRA grants conditional marketing authorization for AbbVie's Tepkinly to treat aggressive blood cancer

AbbVie today announced that the UK Medicines and Healthcare products Regulatory Agency has granted conditional Marketing Authorisation for Tepkinly® (epcoritamab) as a monotherapy for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), after two or more systemic therapies.

28 Oct 2023

CAR T-cell therapy for multiple myeloma shows no difference in survival outcomes by race and ethnicity

Patients with multiple myeloma treated with idecabtagene vicleucel, known as "ide-cel," a chimeric antigen receptor (CAR) T-cell therapy, had no difference in overall survival outcomes regardless of race and ethnicity, according to a study published in Blood Advances.

19 Oct 2023

Racial disparities in survival rates among patients with multiple myeloma and diabetes

Patients with multiple myeloma, a blood cancer of plasma cells in the bone marrow, who also have diabetes have a reduced overall survival when compared to those without diabetes.

29 Sep 2023

Unlocking the power of mRNA vaccines: From COVID-19 to cancer and beyond

A comprehensive review in Signal Transduction and Targeted Therapy delves into the versatility and effectiveness of mRNA vaccines, from their game-changing role in COVID-19 to potential applications in cancer and rare diseases. Despite drawbacks like stability and high immunogenicity, advancements in vaccine technology have poised mRNA platforms as a robust tool for both preventive and therapeutic interventions.

21 Sep 2023

Annual NCCN Congress to focus on latest advances in blood cancer treatment

The National Comprehensive Cancer Network 2023 Annual Congress: Hematologic Malignancies returns to San Francisco this week, for the first time since 2019.

19 Sep 2023

Study reveals potential targets to improve the treatment of myeloma

A ground-breaking study by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has revealed crucial insights into the role of the histone methyltransferase NSD2 and its epigenetic target PKCα in causing t(4;14) translocated multiple myeloma (MM), a high-risk subtype of blood cancer, to be more aggressive and resistant to treatment.

12 Sep 2023

Immune system plays key role in determining the duration of patients' remission from multiple myeloma

A new study from researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and other top-tier cancer centers highlights the vital role that the immune system plays in determining the duration of patients' remission from multiple myeloma.

7 Sep 2023

Scientists develop new technique to study sugars on immune cells

Everyone loves a sweet treat, even our cells. While we typically think of sugar as a component of our diet that gives us energy, sugars are also very important in guiding the activity of our cells.

5 Sep 2023

Universal approach could potentially expand CAR T cell therapy to all blood cancers

A broad new strategy could hold hope for treating virtually all blood cancers with CAR T cell therapy, which is currently approved for five subtypes of blood cancer.

31 Aug 2023

Study finds potential HIV cure using existing cancer drug

An existing blood cancer drug has shown promise in killing 'silent' HIV cells and delaying reinfections – a significant pre-clinical discovery that could lead to a future cure for the disease.

30 Aug 2023

People with compromised immune systems less likely to have COVID-19 antibodies, study finds

New research has identified which people with compromised immune systems are less likely to have COVID-19 antibodies - making them more vulnerable to a severe infection.

23 Aug 2023

NCCN publishes new resource on options, benefits of care approaches for pediatric Hodgkin lymphoma

The National Comprehensive Cancer Network today announced the publication of NCCN Guidelines for Patients®: Hodgkin Lymphoma in Children.

22 Aug 2023

Unveiling hidden threats: clustering loops in CAR-T cells impact cancer therapy

How complementarity-determining region (CDR) loops in the single-chain variable fragment (scFv) influence chimeric antigen receptor (CAR)-T cell behavior.

14 Aug 2023

New gene therapy shows promise for treating fusion-driven cancers

A new study presents a promising treatment method for so-called fusion-driven cancers, which are currently often difficult to cure. These fusion-driven cancers are caused by an error in cell division that creates a fusion of different genes.

11 Aug 2023

Using 'click chemistry' to create novel multi-protein anti-cancer agents

A potent anti-cancer therapy has been created using Nobel prize-winning "click chemistry", where molecules click together like LEGO bricks, in a new study by UCL and Stanford University researchers.

24 Jul 2023

ECOG-ACRIN launches new trial to evaluate nilotinib and paclitaxel for advanced cancers

The ECOG-ACRIN Cancer Research Group has enrolled the first patient in a new treatment trial to evaluate the effectiveness of adding nilotinib to standard paclitaxel chemotherapy.

20 Jul 2023